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A B S T R A C T
Purpose: To describe the spectrum of clinical disease in a mutliplex family with an autosomal dominant
form of generalized epilepsy with febrile seizures plus (GEFS+) and determine its genetic etiology.
Methods: Medical and family history was obtained on 11 clinically affected individuals and their
relatives across three generations through medical chart review and home visits. A candidate gene
approach including haplotype analysis and direct sequencing was used.
Results: An epilepsy-associated haplotype was identiﬁed on 2q24. Direct sequencing of the entire SCN1A
gene identiﬁed seven sequence variants. However, only one of these, c.1162 T > C, was not found in
population controls. This transition in exon 8 of SCN1A predicts a substitution (Y388H) of a highly
conserved tyrosine residue in the loop between transmembrane segments S5 and S6 of the sodium
channel protein (Nav1.1). Clinical features in mutation carriers of this novel missense mutation were
highly variable, ranging from febrile seizures to severe refractory epilepsy.
Conclusion: A novel missense mutation in the pore-forming region of the sodium channel gene SCN1A
causes GEFS+ with a variable phenotype that includes mood and anxiety disorders, as well as ataxia,
expanding the GEFS+ spectrum to include neuropsychiatric disease.
Crown Copyright  2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Generalized epilepsy with febrile seizures plus (GEFS+) is a
diagnostic label coined by Scheffer and Berkovic in 1997 to
describe a dominantly inherited epilepsy disorder associated with
febrile and afebrile seizures. The phenotype is variable and can
range from febrile seizures to severe intractable epilepsy with
developmental delay in affected individuals within the same
family.1,2 GEFS+ is also genetically heterogeneous with ﬁve
causative genes identiﬁed to date. The most widely reported is
SCN1A, which encodes the a1-subunit of a voltage-gated sodium
channel and accounts for mutations in approximately 11% of
previously described GEFS+ families.3,4 Mutations in genes
encoding the b1 and aII-subunits of voltage-gated sodium* Corresponding author at: Discipline of Genetics, Faculty of Medicine, Memorial
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and six missense mutations associated with GEFS+ have been
identiﬁed in SCN1B,5,7,8 and one missense mutation in the SCN2A
gene has been associated with GEFS+ in a single patient.6 In
addition to mutations in subunits of the sodium channel, GEFS+
may also be associated with abnormalities in gamma-aminobu-
tyric acid (GABA) neurotransmission, resulting from mutations
in the GABRG2 and GABRD genes, which encode subunits of the
GABAA, receptor.
9,10 Three missense mutations segregating in
GEFS+ families have been reported in the GABAA receptor, gamma 2
(GABRG2) gene,9,11 while two have been reported in the GABAA
receptor, delta (GABRD) gene.10
The most clinically relevant GEFS+ gene, SCN1A, has 26 exons
and is highly conserved across species.3 Mutations in SCN1A
have been associated with a spectrum of epilepsy phenotypes,
including severe myoclonic epilepsy of infancy (SMEI, also known
as Dravet’s Syndrome), GEFS+, and infantile spasms (IS).12,13 Of the
155 SCN1A mutations currently reported in the Human Gene
Mutation Database (http://www.hgmd.cf.ac.uk), the vast majority
are associated with SMEI, while 19 missense mutations in the
SCN1A gene have been associated with GEFS+.14–16
Recently, the phenotypic spectrum resulting from SCN1A
mutations has been extended to include cryptogenic generalized
and focal epilepsy, familial hemiplegic migraine, and familial. Published by Elsevier Ltd. All rights reserved.
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involving comprehensive clinical data on mutation carriers from
multiplex families are necessary to determine the natural history
and full clinical spectrum associated with the GEFS+ phenotype.
We report a four generation family with autosomal dominant
GEFS+ with a novel mutation in SCN1A, which extends the
phenotypic spectrum associated with GEFS+ to include ataxia
and social anxiety.
2. Methods
2.1. Clinical features
The proband (IV:1, Fig. 1) was ascertained from a registry of all
epilepsy patients treated at the Pediatric Neurology Clinic in the
Janeway Child Health Centre (St. John’s, NL, Canada). The pedigree
was extended through family visits and interviews and further
clinical data was obtained from EEG recordings, standardized
questionnaires (see Supplementarymaterial), andmedical records.
Epilepsy diagnoses were made by pediatric neurologists (DB, MA)
using the International League Against Epilepsy (ILAE) classiﬁca-
tion system.19 Informed consentwas obtained from all participants
or parents/legal guardians. The study was approved by the Human
Investigations Committee of Memorial University (Study No. 4.15).
2.2. Genetic analysis
Genomic DNA was extracted from peripheral blood.20 Sixteen
family members were genotyped for four microstatellite and two
intragenic SNPs spanning SCN1A on chromosome 2q24 (Fig. 1).
Sequencing primers were custom designed using Primer3 (http://
frodo.wi.mit.edu/) to amplify all 26 exons, intron/exon boundaries
and 50 and 30 UTRs of SCN1A (GenBank accession no. AB093548).
Samples were sequenced using BigDye Terminator v.3.1 Cycle
Sequencing Kit and run on an ABI 3130xl (Applied Biosystems).
Sequence traces were inspected manually for quality control and
analyzed using Mutation Surveyor v.3.20. The frequency of
variants were tested against ethnically matched populationFig. 1. Core pedigree of Newfoundland family showing both typical and novel features of G
in the vicinity of SCN1A. Markers are listed on the left and alleles given in size (base pa
masked using diamond symbols to protect conﬁdentiality.controls and the effects of variants were predicted using several
bioinformatics tools available online. Information on speciﬁc
analysis is available upon request.
3. Results
3.1. Clinical features
The founders of this Newfoundland family originate from
County Cork, Ireland. The complete pedigree consists of 97
relatives across ﬁve generations segregating an autosomal
dominant formof epilepsy. The core pedigree depicts 4 generations
(affected branches only) of this family, which includes 11
individuals diagnosed with epilepsy in three successive genera-
tions (Fig. 1). Marked clinical heterogeneity between affected
relatives with a variety of seizure types and neurological deﬁcits
was obtained by reviewing medical records and EEGs, and also
through seizure questionnaires and home visits. All clinically
affected relatives (n = 11) had seizure disorders starting in
childhood with a mean age of onset of 2.1 years (range 0.75–5.5
years) (Table 1). Of these, nine (IV:1, IV:2, IV:3, III:3, III:2, II:7, II:9,
III:12 and III:16) had generalized tonic-clonic seizures (GTCS)
which occurredwith andwithout fever, and two (II:2 and IV:5) had
febrile seizures only. Regarding seizure presentation, ﬁve (IV:1,
IV:2, IV:3, II:7 and III:12) had multiple episodes of status
epilepticus, four (IV:1, IV:2, IV:3 and III:12) had absence seizures,
one (IV:1) had myoclonic seizures, and one (IV:5) had atonic
seizures. Other neuropsychiatric disorders were also prominent,
with ﬁve (IV:1, IV:2, III:2, III:12 and III:16) individuals presenting
intellectual disabilities, three (II:7, II:9 and III:16) with debilitating
psychiatric disease, and two, including the proband (IV:1, III:12),
with ataxia. None of the eight spouses had any personal or family
history of seizures.
The proband (IV:1, Fig. 1) had his ﬁrst seizure (afebrile GTCS) at
11 months of age. He began having myoclonic seizures at 2 years
and by 3 years of age was experiencing approximately 10
myoclonic seizures per day. These seizures were controlled with
divalproic acid and ethosuximide to a rate of one per 2–3 days. InEFS+ associatedwith the epilepsy-associated haplotype (red) on chromosome 2q24
irs) or speciﬁc nucleotide. The proband is indicated by an arrow. Gender has been
Table 1
Clinical features of affected family members.
Pedigree reference
[sex; age]
Age of
onset/
remission
Type of seizures/
number
EEG Neuroimaging
(MRI/CT)
AEDs Intellectual
disability
Psychiatric/other
neurological
disorders
Clinical
classiﬁcation
of epilepsy
IV:1 [m; 8 y] 11 mo./cont. Ab, FS, GTCS, SE,
myoclonus/>100
GSW MRI-normal,
CT-normal
Cont. Moderate DD Ataxia GEFS+
IV:2 [f; 5 y] 1 y/cont. FS, Ab, GTCS,
SE/>50
Bilateral
epileptiform
discharges in
frontal region
CT-normal Cont. Mild DD GEFS+
IV:3 [m; 5 y] 1 y/cont. FS, Ab, GTCS,
SE/>50
Normal CT-normal Cont. GEFS+
III:3 [m; 32 y] 1 y/29 y FS, GTCS/many CT-normal Cont. GEFS+
III:2 [m; 34 y] 1 y/15 y FS, GTCS/5–10 Normal CT-normal Stopped Learning
difﬁculty,
probable
ADHD
GEFS+
II:2 [f; 57 y] 5–6 y/teens FS/2 None FS
II:7 [f; 63 y] Infancy/20–22 y GTCS, SE/>50 Stopped Anxiety/Depressiona GTCS
II:9 [f; 61 y] 4–5 y/23 y FS, GTCS/4 Stopped Social anxiety/
depression
GEFS+
III:12 [f; deceased 27 y]
DNA not available
9 mo./27 y Ab, FS, GTCS,
SE/100s
GSW, Rhythmic
and paroxysmal
slowing
CT-normal Cont. Severe MR Ataxia GTCS Cause
of death:
multiple seizures
III:16 [m; 41y] 5 y/20 y FS, partial to
GTCS/many
Normal CT-normal Cont. Mild DD Social anxietyb GEFS+
IV:5 [f; 4 y] 16 mo./22 mo. FS, atonic/2 Normal None Two atonic
febrile seizures
Key: m, male; f, female; y, years; mo. months; Ab, absence; GTCS, generalized tonic-clonic seizures; FS, febrile seizures; SE, status epilepticus; GSW, generalized spike wave;
AEDs, anti-epileptic drugs; DD, developmental delay; MR, mental retardation; ADHD, attention deﬁcit hyperactivity disorder; cont., continuing.
a Patient was treated in a psychiatric unit.
b Patient lives with his parents and is unable to work due to social anxiety.
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absence seizures despite treatment with valproic acid and
ethosuximide. He has had two episodes of status epilepticus. CT
head scan at 3 years of age was normal. EEG at 3 years of age
showed generalized epileptiform discharges, slowing, and poly-
spike and wave discharges. EEGs at 4, 6 and 7 years of age were
normal. Of particular note are his neurologic signs. At 8 years old he
displays moderate global developmental delay, ataxia and
behavioral concerns. He repeated kindergarten and receives
special education support at school, but has had no developmental
regression. He continues to have GTCS approximately once every
3–4 months and remains on valproic acid. His most recent episode
of status epilepticus was 4 years ago.
The sister of the proband (IV:2) was born at 34 + 3 weeks
gestation (twin A; Fig. 1). Her ﬁrst seizure, a febrile GTCS, occurred
at the age of 1 year 2 weeks. She has since had many GTC and
absence seizures, and has had seven hospital admissions for
episodes of status epilepticus, lasting 30–80 min. EEGs (at 1, 2 and
3 years of age) and a CT head scan (at 2 years of age) were normal.
She is now 5 years old, has mild developmental delay and
infrequent seizures on treatment with topiramate and valproic
acid. Kindergarten entry was delayed by 1 year.Table 2
Sequencing variants identiﬁed in SCN1A (NM_006920) in clinically affected subjects.
Exon/Intron Variant nomenclature Classiﬁcation
Intron 1 c.265-83 A > T Noncoding
Intron 6 c.965-21 C > T Noncoding
Exon 8 c.1162 T > C, p.Y388 Missense
Exon 9 c.1212 A > G, p.V404, rs 7580482 Synonymous
Exon 13 c.2167 T > C Synonymous
Exon 16 c.3310 G > A Missense
Exon 17 c.3472 G > A Missense
a BDGP: Splice Site Prediction by Neural Network.
b NCBI dbSNP.The brother of the proband (IV:3, twin B) experienced his ﬁrst
seizure at the age of 1 year 2 weeks. This was an afebrile partial
seizure progressing to secondary generalized tonic-clonic seizure.
He has since had both febrile and afebrile onset generalized
seizures. He has had two episodes of status epilepticus. EEGs (at 2
and 3 years of age) and a CT head scan (at 1 year of age) were
normal. He is now 5 years old, shows normal cognitive
development and his seizures persist at a rate of approximately
one per 3–6 months, despite treatment with valproic acid. There
have been no reported learning or behavioral issues.
Of the remaining eight affected individuals, all except two have
developed afebrile seizures requiring antiepileptic medication.
Three others have developmental delay, all of whom have a history
of multiple seizures refractory to medication.
3.2. Genetic study
Haplotype analysis conﬁrmed co-segregation of epilepsy with a
haplotype on 2q24 (Fig. 1). Direct sequencing of SCN1A revealed
seven sequence variants that co-segregated on the epilepsy-
associated haplotype (Table 2). However, only one of these, a
c.1162 T > C transition in exon 8 of SCN1A (Fig. 2), was found in allAmino acid change Segregation of alleles/veriﬁcation
No Does not predict a splice sitea
No Does not predict a splice sitea
Yes (Y388H) Heterozygous in all affecteds,
Not present in 190 control alleles
No (V404V) Allele frequency of 42%b
No (V723V) Not heterozygous in affecteds
Yes (A1104T) Not heterozygous in affecteds
Yes (E1158K) Not heterozygous in affecteds
Fig. 2. Sequencing traces (forward direction) showing the heterozygous c.1162
T > C transition in exon 8 of SCN1A of the proband’s (IV:1, Fig. 1) genomic DNA. The
amino acid translations (top) show the Y388H amino acid substitution.
Fig. 3. Conservation of SCN1A in the vicinity of Y388 and location of Y388H within
(NP_008851), Pan troglodytes (XP_515872),Mus musculus (NP_061203), Rattus norvegicu
and Nasonia vitripennis (NP_001128389). The tyrosine (Y) residue at position 388 of the S
(B) Y388H (red triangle) results in the substitution of a neutral polar tyrosine residue to a
SCN1A protein. Segments 5 and 6 (darker blue) form the ion channel pore and segmen
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matched population control chromsomes (Table 2). In addition,
this novel mutation predicted a deleterious replacement of a
highly conserved and uncharged tyrosine to a basically charged
histidine residue within the pore domain of the SCNIA sodium
channel (Fig. 3A and B).
4. Discussion
We report a comprehensive clinical study of a family with an
autosomal dominant history of extended spectrum GEFS+ due to a
novel missense mutation in SCN1A. Although the clinical pre-
sentation is variable, as is the case for GEFS+,1,21–23 seven of the 11
affected individuals presented with neuropsychiatric deﬁcits. Of
the 10 affected individuals known to have the novel SCN1A
mutation, four had developmental delay, three had debilitating
psychiatric disease, and two had ataxia, in addition to epilepsy. The
11th affected individual (III:12; deceased) had severe mental
retardation, ataxia and died as a result of multiple seizures, though
her mutation status is unknown as her DNA was unavailable. This
is the ﬁrst report of familial ataxia in a family with GEFS+ as the
primary presentation. These ﬁndings suggest that the GEFS+
phenotype may include a range of neuropsychiatric deﬁcits, and
testing mutation carriers with neuropsychological scales may be
indicated.
Approximately 20% of cases of GEFS+ have an identiﬁed genetic
cause and most of these have mutations in SCN1A.24 The mutation
identiﬁed in this family, a c.1162 T > C transition in exon 8 of
SCN1A, is novel and located between S5 and S6 in the pore-forming
region of domain 1 of SCN1A. Interestingly, the majority of
mutations in the pore-forming loop regions (between S5 and S6)
have been identiﬁed in patients with SMEI.25 Similar to the GEFS+
phenotype, SMEI is associatedwithwide intrafamilial variability of
phenotype which can include progressive myoclonic epilepsy and
developmental delay.26 In this family, none of the 11 clinically
affected members fulﬁll the diagnostic criteria for SMEI. The
proband (IV:1) had multiple seizure types including myoclonus, inthe SCN1A protein. (A) Weblogo was used to align orthologs from Homo sapiens
s (NP_110502), Danio rerio (NP_956426), Drosophila melanogaster (NP_001036280),
CN1A protein compared to other sodium channel proteins is marked by a red arrow.
polar basic histidine in the loop between the S5 and S6 segments of domain 1 of the
t 4 is the voltage sensor.
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has only occasional seizures on a single antiepileptic medication.
Interestingly, mutations in sodium channel genes have also
been associated with other neuropsychiatric disorders of similar
pathology. For example, panic disorder and Asperger syndrome
were present in two individuals in a GEFS+ family with a missense
mutation in SCN1A, and variants in the SCN1A and SCN2A genes
were observed in six patients with autism.27,28 Heterozygotes for a
null allele of another sodium channel gene, SCN8A, showed a
variety of cognitive defects, including mental retardation and
behavior disorders.29 Recently, a novel missense mutation in
SCN1Awas identiﬁed in a familywith familial hemiplegicmigraine,
widening the phenotype associated with mutation in this gene.17
To date, there have been three other reports of missense
mutations in SCN1A causing GEFS+ located in the loop between S5
and S6. The ﬁrst mutation was identiﬁed in 2001 in GEFS+ patients
with febrile seizures associated with afebrile partial seizures
(domain 3, S5-S6; V1428A, C4283T).30 The second occurred in a
South American family in whom an amino acid substitution was
located in the pore-forming region in domain four of the SCN1A
protein (domain4, S5-S6;D1742E,C5226AorG).Thephenotypewas
highly variable, with some individuals having only febrile seizures,
and others having numerous seizures andmental retardation.15 The
thirdmutationwas identiﬁed in a single patient forwhomno family
history was available. At 6 years of age the patient has well-
controlled seizures and normal cognitive and neurological devel-
opment (domain1, S5-S6;R377Q,G1130A).31 Inaddition,mutations
in the pore-forming regions of SCN1A have been previously
associatedwith ataxia amongst patients with an SMEI phenotype.25
The variable expressivity in this multiplex, multigenerational
family is compatible with the broad phenotypic spectrum
previously observed in other GEFS+ families.1,21–23 Increasing
reports of the high degree of variability in GEFS+ families implies
the presence of modifying inﬂuences including other genes and
environmental factors.32 It also presents challenges in counseling
families regarding prognosis and recurrent risk. Comprehensive
clinical data in mutation carriers suggests that GEFS+ should be
extended to include psychiatric and neurological deﬁcits, based
largely on observations and follow-ups from home visits. Although
often infeasible in clinical studies, family visits and using open
questions can facilitate the collection of phenotypic data that
might otherwise be missed with structured interviews and
standardized questionnaires. The use of neurological scales to
further the extent of neuropsychiatric features resulting from this
novel mutation in SCN1A is underway.
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